EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Induction of immune tolerance in living related human leukocyte antigen–matched kidney transplantation: A phase 3 randomized clinical trial

Dixon B Kaufman, Sanjeev K Akkina, Mark D Stegall, James B Piper, A Osama Gaber, William S Asch, Stephan Busque, Erik Stites, Michael De Vera, Titte R Srinivas, Diane Alonso, Ashesh Shah und 13 weitere

American Journal of Transplantation · 2025-07 · 25 (7) · 1461-1470

DOI: 10.1016/j.ajt.2025.01.044 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Transplantation, 2025-07. Verfasst von Dixon B Kaufman und 24 weiteren Autor:innen. Beteiligte Einrichtung: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Electronic address: kaufman@surgery.wisc.edu. Hauptthemen laut MEDLINE: Kidney Transplantation, HLA Antigens, Living Donors, Graft Rejection. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: California Institute of Regenerative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This phase 3 multicenter, randomized, controlled clinical trial evaluated investigational cellular product (MDR-101) to produce immune tolerance vs standard of care, in kidney transplant recipients. Adult recipients of kidneys from 2-haplotype human leukocyte antigen-matched living siblings were randomized 2:1 to treatment (n = 20) or control (n = 10). The MDR-101 product was from the same kidney donor. Treatment recipients received a nonmyeloablative conditioning protocol with rabbit-antithymocyte globulin and low-dose total lymphoid irradiation (10 fractions). MDR-101 was infused (day 11). Steroids were withdrawn by day 10 and mycophenolate by day 39. Tacrolimus was continued until day 180 and tapered to withdrawal 1-year posttransplant if donor hematopoietic mixed chimerism was ≥5%. Controls received immunosuppression (IS) per institutional standard of care. Twenty recipients received the MDR-101 infusion, and none developed graft versus host disease. Nineteen (95%) successfully discontinued all IS approximately 1 year after kidney transplant. Fifteen (75%) reached the primary study endpoint of IS-free for >2 years. Four resumed IS: 1 with recurrent immunoglobulin A nephropathy; 1 with recurrent immunoglobulin A nephropathy and rejection; 1 with rejection; and 1 with borderline biopsy changes. Kidney transplant recipients receiving MDR-101 achieved donor mixed chimerism and functional immune tolerance for greater than 2 years with no death, graft loss, DSA, or graft versus host disease and demonstrated improved quality of life compared to standard treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationHLA AntigensLiving DonorsGraft RejectionImmune ToleranceKidney Failure, ChronicHumansMaleAdultFemaleMiddle AgedGraft SurvivalFollow-Up StudiesTransplantation ConditioningPrognosisKidney Function TestsImmunosuppressive Agents

Stichwörter der Autor:innen

chimerismimmunosuppression-freekidney transplantationtolerance

Substanzen

HLA AntigensImmunosuppressive Agents

Autor:innen und Institutionen

  • University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Electronic address: kaufman@surgery.wisc.edu.
  • Loyola University Medical Center, Maywood, Illinois, USA.
  • Mayo Clinic, Rochester, Minnesota, USA.
  • Inova Fairfax Hospital, Falls Church, Virginia, USA.
  • Houston Methodist Hospital, Houston, Texas, USA.
  • Yale School of Medicine, New Haven, Connecticut, USA.

Förderung

  • California Institute of Regenerative Medicine

Zitieren

APA

Kaufman, D. B., Akkina, S. K., Stegall, M. D., Piper, J. B., Gaber, A. O., Asch, W. S., Busque, S., Stites, E., De Vera, M., Srinivas, T. R., Alonso, D., Shah, A., Patel, A., Mai, M. L., Chavin, K. D., DebRoy, M., Jittirat, A., Costa, N., Cooper, M., …, & MDR-101-MLK Study Group (2025). Induction of immune tolerance in living related human leukocyte antigen–matched kidney transplantation: A phase 3 randomized clinical trial. American Journal of Transplantation, 25(7), 1461-1470. https://doi.org/10.1016/j.ajt.2025.01.044

Vancouver

Kaufman DB, Akkina SK, Stegall MD, Piper JB, Gaber AO, Asch WS, et al. Induction of immune tolerance in living related human leukocyte antigen–matched kidney transplantation: A phase 3 randomized clinical trial. American Journal of Transplantation. 2025;25(7):1461-1470. doi:10.1016/j.ajt.2025.01.044

BibTeX
@article{Kaufman2025,
  author = {Kaufman, Dixon B and Akkina, Sanjeev K and Stegall, Mark D and Piper, James B and Gaber, A Osama and Asch, William S and Busque, Stephan and Stites, Erik and De Vera, Michael and Srinivas, Titte R and Alonso, Diane and Shah, Ashesh and Patel, Anup and Mai, Martin L and Chavin, Kenneth D and DebRoy, Meelie and Jittirat, Arksarapuk and Costa, Nadiesda and Cooper, Matthew and Vranic, Gayle and Laftavi, Mark R and Saidi, Reza F and Collette, Suzon and Brennan, Daniel C and MDR-101-MLK Study Group, MDR-101-MLK Study Group},
  title = {Induction of immune tolerance in living related human leukocyte antigen–matched kidney transplantation: A phase 3 randomized clinical trial},
  journal = {American Journal of Transplantation},
  year = {2025},
  volume = {25},
  number = {7},
  pages = {1461--1470},
  doi = {10.1016/j.ajt.2025.01.044}
}
Kostenlos starten →